Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis

OverTTuRe: An Observational Multi-Country Study Collecting Real-World Secondary Data on the Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The overall aim of this observational study is to generate real-world evidence on the pre- and post-diagnosis disease journeys, including baseline characteristics, treatment patterns and selected clinical, economic, and humanistic outcomes (for example Health Related Quality of Life (HRQoL), Neuropathy impairment score, activities of daily living (ADL) assessments) in patients with ATTR amyloidosis, and to better understand how the disease is presented.

Who May Be Eligible (Plain English)

Who May Qualify: - Patients aged \>18 years at study index date AND - A reported diagnosis code for amyloidosis OR - A claim for ATTR-specific treatment OR - A positive biopsy for amyloidosis and positive immunostaining result of biopsy for ATTR Who Should NOT Join This Trial: - Evidence of primary (AL) and secondary (AA) amyloidosis AND/OR - At least one claim/procedure code for stem cell transplant or at least two claims/procedure codes for chemotherapy and autoimmune conditions (where your immune system attacks your own body) drugs which may represent AL (primary) or AA (secondary) amyloidosis treatments Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Patients aged \>18 years at study index date AND * A reported diagnosis code for amyloidosis OR * A claim for ATTR-specific treatment OR * A positive biopsy for amyloidosis and positive immunostaining result of biopsy for ATTR Exclusion Criteria: * Evidence of primary (AL) and secondary (AA) amyloidosis AND/OR * At least one claim/procedure code for stem cell transplant or at least two claims/procedure codes for chemotherapy and autoimmune disease drugs which may represent AL (primary) or AA (secondary) amyloidosis treatments

Treatments Being Tested

OTHER

no intervention

not applicable, this is an observational retrospective data analysis study; no interventions in the study

Locations (20)

Research Site
Eden Prairie, Minnesota, United States
Research Site
Calgary, Alberta, Canada
Research Site
Beijing, China
Research Site
Changsha, China
Research Site
Chengdu, China
Research Site
Guangzhou, China
Research Site
Wuhan, China
Research Site
Horsens, Denmark
Research Site
Berlin, Germany
Research Site
Tokyo, Japan
Research Site
Lisbon, Portugal
Research Site
Porto, Portugal
Research Site
A Coruña, Spain
Research Site
Barcelona, Spain
Research Site
Bilbao, Spain
Research Site
El Palmar, Spain
Research Site
Huelva, Spain
Research Site
Las Palmas de Gran Canaria, Spain
Research Site
Madrid, Spain
Research Site
Majadahonda, Spain